Clinical Trial Update: Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of a Phase I/II clinical study evaluating forodesine in Japanese patients with recurrent or refractory peripheral T-cell ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Forodesine (forodesine)

Snippet

Sponsor: Mundipharma K.K. | Conditions: Recurrent or Refractory PTCL | Phase 1, Phase 2 | Status: COMPLETED